NOP2-mediated m5C methylation of XPD is associated with hepatocellular carcinoma progression

Hepatocellular carcinoma (HCC) is a common malignant tumor with high mortality.Our previous study has confirmed that XPD acts as an anti-oncogene and is downregulated in HCC.The mechanism of XPD downregulation in HCC is unclear.In this work, we obtained the datasets related to HCC patients from GSE76427, LIRI-JP, and TCGA-LIHC cohorts.Among 15 m 5 C regulators (NSUN2, NSUN3, NSUN4, NSUN5, NSUN6, NSUN7, DNMT1, TRDMT1, DNMT3A, DNMT3B and NOP2, TET1, TET2, and TET3, ALYREF), 14 m 5 C regulators were upregulated in tumor tissues of HCC patients, except for TET2.HCC patients were divided into Cluster A and B with different m 5 C methylation patterns.Cluster B was enriched in metabolism-related signaling pathways, and Cluster A was prominently associated with the cell cycle signaling pathway.Moreover, XPD was positively correlated with NOP2.Cluster B exhibited upregulation of XPD and had an obvious survival advantage with respect to Cluster A. Additionally, NOP2 and XPD were downregulated in HCC tumors and cells.In vitro assays revealed that NOP2 overexpression enhanced XPD expression by elevating the m 5 C methylation of XPD, which contributed to inhibit proliferation, migration, and invasion of HCC cells.In conclusion, this work demonstrated that XPD mRNA stability was elevated by NOP2-mediated m 5 C methylation modification and then inhibited the malignant progression of HCC, suggesting that XPD may be a potential target for HCC treatment.